Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Me? I'm sitting on the dock of the Bay waiting for my ship to roll in. Glad there will be dockworkers to unload.
Ok Mozy here's my opinion since you asked.
You are obviously nervous based on past experience when your were greedy and didn't take any money of the table even when stock was close to a buck. Your present total cost is $47,000. Why don't you sell 125,000 here for $49,000 and you will own 400,000 shares free and clear. You will sleep much better and if the worst happens and Vyvanse is not approved, you can buy back shares much cheaper since the stock would likely fall.
Feel better? Good luck.
Expect at least two important new events within the next 5 weeks. Vyvanse of course is the big one circa November 15. As they used to say about the lottery:you gotta be in it to win it. Going much higher kids. The Be fot Concrrta could also be on the table soon..
Year end rally. Welcome 5785.
Maybe he can take us all up on a ride in Las Vegas. You really went for a blast from the past didn't you?
The announcement of the hiring of Ergomed to conduct the 212 patient clinical trial has the important tidbit that the trail is expected to be commenced during the 1st quarter 2025. This stock will be subject to tax loss selling this quarter but should be a good purchase in January 2025. It may break the $1 mark and again be subject to possible delisting.
But I'm in a New York state of mind.
One of the advantages of taking risks when you are young is that you have enough time to take chances and overcome any mistakes. Good luck kid.
When approval in England is announced, this company becomes an immediate takeover candidate by one of the major drug company that can easily fund the manufacturing capacity and the costs of filing for FDA approval. This can be a major event in the fight against cancer. There is no way to put a realistic number on that.
The Sackler family allegedly wants to use Oxycontin funding to address opioid addiction. The recent US Supreme Court decision recently blocked a $6B settlement in Bankruptcy Court that would have given the Sackler family immunity. And you want me to help you understand. I'm not that smart.
The stay saves Elite thousands of dollars in legal expenses as the parties await the decision on the Purdue appeal of the Accord victory on the validity of its Oxycontin patent. Apparently both opposing attorneys in the Elite case agree that the issue of the validity of Elite's patent will be moot if Purdue loses its' appeal.
Again ,like a fellow a fellow poster here, I believe that if Purdue loses it may strike a deal with Elite. All good stuff for shareholders.
The next 6-8 weeks may be the most crucial for shareholders here both new and old Obviously the decision on the appeal of Judge Bryson's decision in favor of Accord which will be argued of October 7, will have huge ramifications in the Purdue v. Elite patent infringement claim. I would expect the Circuit Court of Appeal to make a decision sometime in early November. Should, as many expect, it be in favor of Accord, the Elite attorneys may make a motion to dismiss Purdue's claim as moot having caused a collateral estoppel of the claim involving the same issue in Accord which deemed the patent valid. Needle mover 1 will be closer to fulfillment.
I also believe that the PDUFA date for Vyvanse will be circa November 20. A positive decision will generate Needle Mover 2 with the company indicating it is ready to do a launch as early as sometime in December.
Also in November if is likely that the FDA and DEA will certify the new storage facility which will free up massive space in the production facility to produce, more Adderall, Vyvanse, Methotrexate, and Tylenol with Codeine.
Finally. in mid November there will be the conference call for the 2nd quarter.
Investors here are likely to have a lot to be thankful for as Thanksgiving ends the month.
Hi True. Nice to see that we have outlived Billy the Squid. Still have 500 shares after split shares but did make a few pennies a few years ago when it moved on a meme. Thanks for the memeories. I too have some money to invest and I am looking at the Trustunits Foundation.
arca was pulled. back to 14 mms on ih site
Looks like 2 new MMs. ARCA and STXG. The former trades NYSE issues electronically. HMM.
Investing is all about timing. Duh. You only have to be right once just. See Thomas Edison. The issue of approval should be resolved, one wat or the other, before the end of the year. You gotta be in it to win it. Risk/Reward here tilts toward reward as the stock remains a disappointment.......until it's not. Money Talks and Bullshit Walks.
With the latest result indicating an over 80% Survival rate after 5 years as opposed to under 50% without Multikine, it appears that approval is a foregone conclusion after the confirmatory study succeeds. Stock remains a strong buy.
Will nwbo be presenting at the ESMO Convention which started today in Barcelona.? TIA
Oh ye of little faith. It will be interesting to see what they say at the conference in Barcelona tomorrow.
Most reads 1 million on IH #1.
Hi Sleuth. When you get a chance can you get the latest Court memo regarding the stay in District Court. Since the Accord case is now closed, it would appear the stay should or will be vacated soon. TIA.
Highest volume in over 1 month. Hmmm
Wake up little Susie. Wake up.
There are two Price/Earnings ratios. The P/E cited here has been the trailing P/E ratio which is based upon the past years revenue stream. The forward P/E is a better indicator for this stock as most here can anticipate a big increase in revenue compared to the last fiscal year of $56M. If projections about Vyvanse are correct, and 3 more ANDAs are launched, a $100M fiscal 2025 seems possible. My long winded point is that the current P/E cited is way too conservative.
CVM to present new data for Multikine at the European Society for Medial Oncology 2024 Medical Oncology Congress Saturday 9/13/24 in Barcelona Spain.
Expect the stay in Purdue v. Elite to be lifted in the near future. While I agree with Jour that is is not a material event, the lift of the stat will be indicated on the Curt document and available for our resident sleuth who is also doing excellent work on behalf of this board of shareholders and naysayers.
Great due diligence. You and Nas are the best source of good and helpful data sine the late great N2K. Keep up the good work.
All quiet on the Western front.
Go to settings. Hit ignore list and and click on he party you ignored. You will get their latest posts. But why waste time with bad vibes?
My guess is that the stay will be lifted and either a discovery order will be issued or Purdue will file a motion to dismiss. I expect that Purdue will appeal the final Judgment which may cause the Court to continue the stay in our case. In any event very good news indeed albeit the journey will not be short.
The broken record won't be back until October 1.
The filing for an ANDA for Concerta looms as the third blockbuster and, as Jour points out, may indeed produce more revenue than Vyvanse given less competitors. Apparently this filing is awaiting the successful completion of BE study which Hakim has indicated is underway some time ago.
I am looking forward to a possible filing before the end of the year with the new revenue baby due 10 months thereafter. If this company ends up selling Adderall, Vyvanse and Concerta, it may indeed deserve a market cap in excess of a billion bucks or more.
Excellent information. Elite seems to meet many of the criteria for a buyout.
There are now 13 MMs trading this stock.
Ditto. I can't container my emotions on this one.
Looks like a Freudian Typo. Staristics: Definition a Corp that produces revenue that is out of this world.
Can you explain why the company name Vivos, which can be confused with Vivos Therapeutics, does not change its name to RadioGel? As I am a newbie, please excuse my ignorance.
Do you have a guess on what a fair market cap would be if RadioGel is approved? Current 56 million cap, before the offering is completed, seems low. I think $500m, or $1.30, seems about right for the coming year. Please go easy on me.
Many of the "works on Wall Street" guys are critical of OTC stocks as many brokerages refuse to trade them since they are not marginable and may not be shorted (market makers accepted). That being said, investors here should not be deterred from holding a nice position in a stock which will eventually be on Nasdaq or be a part of a NYSE stock which took them over. We are doing just fine without the smart money guys who don't appreciate that YTD Elite has outpaced even the great Nividia results.
It is amazing that investors don't realize that when CVM reveals that they have enrolled the 212 patients to do the confirmatory study, this stock will move higher. If the study shows good preliminary results, they may be fast tracked. Watch for volume surge in the near future. As for the timeline, if they are able to enroll 53 patients a month on average, they would reach the quota on September 8. I'm locked and loaded here.
Took a nice opening position here. Assuming a fda go ahead by mid September, I am still unsure of the market potential for both radiogel and isopet. Another unknown is the status of the $60M stock offering.
It was good to see that the CEO with a massive stock position still opted to buy cheap shares which is a positive. With a current market cap of only $56M, this is a strong temping buy. If one conservatively believes this company could be worth $500M market cap or more, this could be a 10 bagger. Stock being held down by the going concern caveat, but if they get the needed financing, this can be a big winner. But the days grow short when you reach September.